Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kunal Chaudhary

Nephrology Columbia, MO Medical Doctor

NPI 1528019809 CMS profile 205165

1 Hospital Dr, Columbia, MO 65212

Open in the dashboard

General payments

$36,142

164 records reported · program years 2019–2025

Research payments

$998

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$148,743 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Kunal Chaudhary of Columbia, MO is reported in the CMS Open Payments database as having received $36,142 across 164 general payments and $998 in research payments paid to them. Separately, studies naming them as principal investigator received $148,743 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $420 21
2024 General $1,989 35
2023 General $196 10
2022 General $3,061 13
2021 General $1,233 2
2020 General $6,351 20
2019 General $22,892 63
2019 Research $998 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kunal Chaudhary
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Kunal Chaudhary were reported at $420. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Kunal Chaudhary Nephrology median Middle half National median
2019 $22,892 $236 $90–$588 $163
2020 $6,351 $135 $46–$364 $114
2021 $1,233 $202 $67–$551 $132
2022 $3,061 $242 $77–$695 $149
2023 $196 $254 $84–$766 $160
2024 $1,989 $300 $99–$852 $164
2025 $420 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $33,331 85 payments
  2. AstraZeneca Pharmaceuticals LP $1,396 13 payments
  3. Amgen Inc. $286 6 payments
  4. Retrophin, Inc. $286 20 payments
  5. Calliditas Therapeutics US Inc. $140 5 payments
  6. Relypsa, Inc. $99 6 payments
  7. Baxter Healthcare $84 3 payments
  8. Akebia Therapeutics Inc $74 5 payments
  9. Mallinckrodt Hospital Products Inc. $73 4 payments
  10. Novartis Pharmaceuticals Corporation $52 2 payments
  11. Other $321 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,722 15 payments
  2. Travel and Lodging $5,726 32 payments
  3. Food and Beverage $3,691 116 payments
  4. Education $3 1 payment
Products named General payments · program years 2019–2025
  1. JYNARQUE Nephrology $21,598 38 payments
  2. JYNARQUE Nephrology $10,196 32 payments
  3. SAMSCA $1,031 9 payments
  4. TAVNEOS $264 5 payments
  5. TARPEYO $96 3 payments
  6. Auryxia $74 5 payments
  7. Renal - PD $73 2 payments
  8. TERLIVAZ $73 4 payments
  9. Veltassa $65 4 payments
  10. Fabhalta $52 2 payments
  11. Other $450 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $998 13 payments

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record